PLX vs TGT · P/E 31, rev $53.6M vs P/E 17, rev $51.98B
Protalix Biotherapeutics Inc (PLX) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
Target Corporation (TGT) is a discount stores company listed on NYSE.
Latest reported PLX revenue for 2026-06-30 was $53.6M. Net income was $22.1M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
PLX currently screens at market cap $122.6M and trailing P/E 30.8. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the PLX and TGT stock pages for the full models.
Not investment advice.